Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study
Authors:
- Yves LacourcièreYLYves Lacourcière
- Jackson T. WrightJWJackson T. Wright
- Rita SamuelRSRita Samuel
- Dion ZappeDZDion Zappe
- Das PurkayasthaDPDas Purkayastha
- Henry R. BlackHBHenry R. Black
- 1 June 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Blood Pressure Monitoring
- Vol. 14 (3) , 112-120
Abstract
Previous studies using the combination of angiotensin-receptor blockers and hydrochlorothiazide (HCTZ) have shown superior ambulatory blood pressure (ABP) reduction in study participants with stage 2 hypertension compared with monotherapy. This multicenter, double-blind, parallel group, forced-titration study of individuals with stage 2 hypertension, compared the efficacy of valsartan and amlodipine in combination with HCTZ on ABP reduction. After a 2-week washout period, participants (n=482) with mean office sitting systolic BP >or=160 mmHg and <or=200 mmHg were randomized to receive treatment with either valsartan 160 mg (n=241) or amlodipine 5 mg (n=241), force-titrated to a maximum dose of valsartan/HCTZ 320/25 mg or amlodipine/HCTZ 10/25 mg over 6 weeks and continued through week 10. The primary endpoint was change in mean 24-h ambulatory systolic BP from baseline to week 10. At week 10, changes from baseline in mean office BP were significantly (P<0.0001) decreased by both valsartan/HCTZ (-34.2/-14.2 mmHg) and amlodipine/HCTZ (-34.1/-14.7 mmHg). Changes from baseline in mean 24-h ABP were significantly (P<0.0001) decreased by both valsartan/HCTZ (-21.1/-12.5 mmHg) and amlodipine/HCTZ (-18.1/-9.9 mmHg). However, treatment with valsartan/HCTZ provided significant additional systolic BP (-3.8 mmHg; P=0.0042) and diastolic BP (-2.7 mmHg; P=0.0002) reduction compared with the amlodipine/HCTZ group. The proportion of individuals reaching the office goal BP (<140/80 mmHg) were similar in the valsartan/HCTZ (55.3%) versus amlodipine/HCTZ (54.9%) group, ABP control rates for the recommended ABP goal (<130/80 mmHg) were greater (P=0.0170) in the valsartan/HCTZ group (54.3%) than the amlodipine/HCTZ group (42.7%). Both treatments were well tolerated. On the basis of ABP monitoring but not office measurements, the fixed-dose combination of valsartan/HCTZ is a significantly more effective treatment regimen than amlodipine/HCTZ, with similar tolerability.Keywords
This publication has 20 references indexed in Scilit:
- Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertensionBlood Pressure Monitoring, 2008
- A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertensionCurrent Medical Research and Opinion, 2008
- 2007 ESH-ESC Practice Guidelines for the Management of Arterial HypertensionJournal Of Hypertension, 2007
- Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: A double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adultsClinical Therapeutics, 2007
- Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: Pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trialsClinical Therapeutics, 2005
- Antihypertensive Efficacy and Tolerability of Two Fixed-Dose Combinations of Valsartan and Hydrochlorothiazide Compared with Valsartan Monotherapy in Patients with Stage 2 or 3 Systolic Hypertension: An 8-Week, Randomized, Double-Blind, Parallel-Group TrialClinical Therapeutics, 2005
- VALUE: analysis of resultsThe Lancet, 2004
- Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialThe Lancet, 2004
- Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertensionAmerican Journal of Hypertension, 2003
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003